期刊： KIDNEY CANCER, 2023; 7 (1)
BACKGROUND: Renal cysts are the most frequently occurring incidental renal lesions. They are asymptomatic, which explains why they tend to be diagnose......
期刊： KIDNEY CANCER, 2023; 7 (1)
BACKGROUND: The influence of age and comorbidities during decision-making for patients with renal cell carcinoma remains controversial. OBJECTIVE: To ......
期刊： KIDNEY CANCER, 2023; 7 (1)
Background: Introduction of immune checkpoint inhibitors in the standard of care for metastatic renal cell carcinoma (mRCC) requires robust but yet si......
期刊： KIDNEY CANCER, 2023; 7 (1)
Objective: To evaluate the effectiveness and safety profile of the tyrosine kinase inhibitor Axitinib for patients with advanced or metastatic renal c......
期刊： KIDNEY CANCER, 2023; 7 (1)
Background: The nephrotoxicity profile of contemporary first-line regimens for treatment of metastatic renal cell carcinoma (mRCC) has not been system......
期刊： KIDNEY CANCER, 2023; 7 (1)
Background: Non-clear cell renal cell carcinoma (nccRCC) is a diverse group of cancers that occurs in approximately 25% of patients with renal cell ca......
期刊： KIDNEY CANCER, 2023; 7 (1)
BACKGROUND: Papillary renal cell carcinoma (PRCC) has a relatively poor prognosis in the metastatic setting. In contrast to clear cell kidney cancer, ......
期刊： KIDNEY CANCER, 2023; 7 (1)
BACKGROUND: The historical standard of care for locally advanced renal cell carcinoma (RCC) is nephrectomy + active surveillance. Despite a high recur......
期刊： KIDNEY CANCER, 2023; 7 (1)
Immune checkpoint inhibitors (ICIs) have transformed the management of advanced renal cell carcinoma (RCC), but most patients still do not receive a l......
期刊： KIDNEY CANCER, 2023; 7 (1)
The standard of care for localized renal cell carcinoma (RCC) is radical or partial nephrectomy. Despite complete resection, a subset of patients will......
期刊： KIDNEY CANCER, 2023; 7 (1)
Background: Ipilimumab plus nivolumab is approved as a first-line treatment for intermediate or poor risk metastatic renal cell carcinoma (mRCC). Howe......
